Home Your basket
• Papillary thyroid microca...
   Price 10.50 €
• Principes underlying the ...
   Price 10.50 €
• Melanotic neuroectodermal...
   Price 8.50 €
• Vertical extended hemi cr...
   Price 5.50 €
• Tuberculosis of the laryn...
   Price 5.50 €
• Early PTH assay after tot...
   Price 10.50 €
• Hypersensitivity to inhal...
   Price 10.50 €
• Nasal septal abscess: A c...
   Price 5.50 €
• Neuroplasticity in the au...
   Price 10.50 €
• Parathyroid cervical haem...
   Price 8.50 €
• Usher type I syndrome in ...
   Price 10.50 €
• Petrosal presigmoid appro...
   Price 8.50 €
• Sphenoid arachnoidocele: ...
   Price 8.50 €
• Tuberculous otomastoiditi...
   Price 5.50 €
• Cervical cystic lymphangi...
   Price 5.50 €
• Is ethmoidal adenocarcino...
   Price 10.50 €
• Prosthetics gains and sat...
   Price 12.50 €
• Rhinoplasty: Advantages a...
   Price 10.50 €
• Botulinum toxin in the lo...
   Price 14.00 €
• Pharyngolaryngectomy for ...
   Price 10.50 €
• Management of cervical ce...
   Price 10.50 €
• Ectopic ossification in t...
   Price 5.50 €
• Presentation of a prototy...
   Price 10.50 €
• Rhinophyma in a black afr...
   Price 5.50 €
• A clinical respiratory ev...
   Price 10.50 €
• Going from the tube feedi...
   Price 8.50 €
• Functional septal surgery...
   Price 10.50 €
• The verrucous laryngeal c...
   Price 5.50 €
• Dynamic palatography: Dia...
   Price 12.50 €
• Social consequence of a d...
   Price 10.50 €
• The nasal framework in rh...
   Price 10.50 €
• Transit time of swallowin...
   Price 10.50 €

Total Order 293.50 €

contents
2019
   N# 1 |
2018
   N# 1 | 2 | 3 | 4 | 5 |
2017
   N# 1 | 2 | 3 | 4 | 5 |
2016
   N# 1 | 2 | 3 | 4 | 5 |
2015
   N# 1 | 2 | 3 | 4 | 5 |
2014
   N# 1 | 2 | 3 | 4 | 5 |
2013
   N# 1 | 2 | 3 | 4 | 5 |
2012
   N# 1 | 2 | 3 | 4 | 5 |
2011
   N# 1 | 2 | 3 | 4 | 5 |
2010
   N# 1 | 2 | 3 | 4 | 5 |
2009
   N# 1 | 2 | 3 | 4 | 5 |
2008
   N# 1 | 2 | 3 | 4 | 5 |
2007
   N# 1 | 2 | 3 | 4 | 5 |
2006
   N# 1 | 2 | 3 | 4 | 5 |
2005
   N# | 1 | 2 | 3 | 4 | 5 |
2004
   N# 1 | 2 | 3 | 4 | 5 |
2003
   N# 1 | 2 | 3 | 4 | 5 |
2002
   N# 1 | 2 | 3 | 4 | 5 |
2001
   N# 1 | 2 | 3 | 4 | 5 |
2000
   N# | 1 | 2 | 3 | 4 | 5 |
1999
   N# 1 | 2 | 3 | 4 | 5 |
1998
   N# 1 | 2 | 3 | 5 |
1997
   N# 1 | 2 | 3 | 4 | 5 |
1996
   N# 4 | 5 |

Click on the number of the review to see the content
Teaching bulletin CME
List of all teaching bulletins CME.
Editor reading committee
Editor reading committee.
To publish...
Instructions for authors
Archives Press and Books
Select of books and press articles.
Mailing list
News information letter.
Subscription prices


If you wish to adjust the size of the displayed characters, click in the high menu on "Your account" and choose the desired size.



  Contents > Previous page > Article detail print Order
o Issue N# 1 - 2005 o

RHINOLOGY

Treatments of hereditary hemorrhagic telangiectasia of the nasal mucosa


Authors : E. Babin, M. Borsik, S. Braccard, L. Crampette, V. Darrouzet, F. Faure, J. P. Fontanel, E. Houdart, R. Jankowski, G. Le Clech, L. Malvezzi, S. Morini, S. Perie, J. Perret, J. C. Pignat, F. Portier, E. Serrano, H. Plauchu (France - Italie)

Ref. : Rev Laryngol Otol Rhinol. 2005;126,1:43-48.

Article published in french
Downloadable PDF document french



Summary : Hereditary Hemorrhagic Telangiectasia is a systemic autosomal dominant disorder involving blood vessels. The most common symptom is reccurent epistaxis. The treatments of these epistaxis are numerous but such treatments are often symptomatic and their effects are often not sustained. Some of these treatments may be complicated by visceral vascular malformations. The aim of this study is to propose a treatment plan for these patients with hierarchical organisation of therapeutic options taking into account of their previous therapy. Method: H. Plauchu organized in Paris, december 2002 a meeting with any medical specialists of this diesease. They have analysed variety of therapies that have been proposed for epistaxis control in Hereditary Haemorrhagic Télangiectasia. Results: Most common use packing of nasal fossa and then hyperselective embolization of the internal maxillary and facial arteries for severe epistaxis. For chronic epistaxis, best treatment use sclerotics products (Ethibloc®) and laser. After discussion, primary embolization could be useful to reduce vascularization of nasal fossa. Conclusion: Treatment of epistaxis in Hereditary Haemorrhagic Telangiectasia could increase in few years. Use of an index card of for epistaxis in the disease of Rendu-Osler could help to find treatment of choice.

Price : 10.50 €      order
|


Subscribe online - Pay by credit card!


© Copyright 1999-2024 - Revue de Laryngologie   Réalisation - Hébergement ELIDEE